Q2

Isofol Medical AB (publ) publishes interim report, January–June 2024

GOTHENBURG, Sweden, August 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–June 2024 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Second quarter, April–June 2024 Net revenue amounted to kSEK 0 (0) and […]

Isofol Medical AB (publ) publishes interim report, January–June 2024 Read More »

Isofol Medical AB (publ) publishes interim report, January–June 2023

GOTHENBURG, Sweden, August 22, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–June 2023 is now available on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Second quarter, April–June 2023 Net revenue amounted to TSEK 0 (4,027) and other revenue

Isofol Medical AB (publ) publishes interim report, January–June 2023 Read More »

Isofol Medical AB (publ) publishes interim report, January–June 2022

GOTHENBURG, Sweden, August 23, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–June 2022 is now available on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Second quarter, April–June 2022 Net revenue amounted to TSEK 4,027 (7,333) and other revenue

Isofol Medical AB (publ) publishes interim report, January–June 2022 Read More »

Scroll to Top